Выход
Вход/Login
 
E-mail
Пароль/Password
Забыли пароль?
Введите E-mail и жмите тут. Пароль будет выслан на указанный адрес
Войти (LogIn)

 

Если вы первый раз здесь, то зарегистрируйтесь

Регистрация/Sign Up
Полное имя (Ф И О)/Full name
E-mail
Телефон/Phone
Зарегистрироваться,
на ваш E-mail будет выслан временный пароль

 

Медицинская литература. Новинки


 

 

 

 

 
вce журналы << Эндокринная хирургия << 2013 год << №2 <<
стр.17
отметить
статью

Клинические рекомендации Европейской тиреоидологической ассоциации по метастатическому медуллярному раку щитовидной железы

Перевод В.В. Воскобойникова, Д.Г. Бельцевича, В.Э. Ванушко
Вы можете загрузить полный текст статьи в формате pdf
-
Адрес для корреспонденции: Бельцевич Дмитрий Германович – 117036 Москва, ул. Дм. Ульянова, д. 11. Email: beltsevich@rambler.ru

Отдаленные метастазы являются главной причиной смерти пациентов с медуллярным раком щитовидной железы (МРЩЖ). Рекомендации сфокусированы на пациентах с отдаленными метастазами МРЩЖ. Составлен подробный протокол наблюдения пациентов с биохимическим или топическим подтверждением этого заболевания, отражены критерии эффективности лечения, включая местные и системные варианты лечения, основанные на результатах последних исследований. Пациенты с бессимптомным течением болезни с низкой степенью опухолевого поражения и стабильным течением заболевания имеют положительный прогноз после местного лечебного воздействия и должны постоянно наблюдаться через определенные регулярные промежутки времени. Обследование проводится каждые 6–12 мес или через более длинные интервалы в зависимости от времени удвоения кальцитонина крови и раковоэмбрионального антигена (РЭА). Пациенты с распространенным опухолевым поражением и прогрессированием заболевания должны получать системное лечение. Большой прогресс в лечении достигнут с началом использования таргетной терапии мультикиназными ингибиторами, но необходимы дальнейшие исследования по улучшению результатов лечения

Ключевые слова:
медуллярный рак щитовидной железы, метастазы, ингибиторы тирозин киназы, RET.

Литература:
1. Kloos R.T., Eng C., Evans D.B. et al. Medullary thyroid can
cer: management guidelines of the American Thyroid
Association. Thyroid. 2009; 19: 565612.
2. Atkins D., Eccles M., Flottorp S. et al. GRADE Working Group:
Grading quality of evidence and strength of recommenda
tions. BMC Health Serv. Res. 2004; 22 (4): 38.
3. Swiglo B.A., Murad M.H., Schünemann H.J. et al. A case for
clarity, consistency, and helpfulness: stateoftheart clinical
practice guidelines in endocrinology using the grading of re
commendations, assessment, development, and evaluation
system. J. Clin. Endocrinol. Metab. 2008; 93: 666673.
4. Guyatt G., Gutterman D., Baumann M.H. et al. Grading
strength of recommendations and quality of evidence in cli
nical guidelines: report from an American College of Chest
Physicians task force. Chest. 2006; 129: 174181.
5. Schlumberger M., Carlomagno F., Baudin E. et al. New the
rapeutic approaches to treat medullary thyroid carcinoma.
Nat. Clin. Pract. Endocrinol. Metab. 2008; 4: 2232.
6. Giraudet A.L., Vanel D., Leboulleux S. et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin le
vels. J. Clin. Endocrinol. Metab. 2007; 92: 41854190.
7. van Heerden J.A., Grant C.S., Gharib H. et al. Longterm
course of patients with persistent hypercalcitoninemia after
apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 1990; 212: 395400, discussion 400401.
8. Pellegriti G., Leboulleux S., Baudin E. et al. Longterm out
come of medullary thyroid carcinoma in patients with normal
postoperative medical imaging. Br. J. Cancer. 2003; 88:
15371542.
9. Fialkowski E., Debenedetti M., Moley J. Longterm outcome of
reoperations for medullary thyroid carcinoma. Wld J. Surg.
2008; 32: 754765.
10. Saad M.F., Fritsche H.A. Jr., Samaan N.A. Diagnostic and
prognostic values of carcinoembryonic antigen in medullary
carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 1984;
58: 889894.
11. Miyauchi A., Onishi T., Morimoto S. et al. Relation of doubling
time of plasma calcitonin levels to prognosis and recurrence of
medullary thyroid carcinoma. Ann. Surg. 1984; 199: 461466.
12. Tisell L.E., Dilley W.G., Wells S.A. Jr. Progression of post
operative residual medullary thyroid carcinoma as monitored
by plasma calcitonin levels. Surgery. 1996; 119: 3439.
13. Giraudet A.L., Al Ghulzan A., Aupérin A. et al. Progression of
medullary thyroid carcinoma: assessment with calcitonin and
carcinoembryonic antigen doubling times. Eur. J. Endocrinol.
2008; 158: 239246.
14. Barbet J., Campion L., KraeberBodere F., Chatal J.F. Prognostic impact of serum calcitonin and carcinoembryonic anti
gen doublingtimes in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2005; 90: 60776084.
15. Oudoux A., Salaun P.Y., Bournaud C. et al. Sensitivity and
prognostic value of positron emission tomography with F18
fluorodeoxyglucose and sensitivity of immunoscintigraphy in
patients with medullary thyroid carcinoma treated with anti
carcinoembryonic antigentargeted radioimmunotherapy. J.
Clin. Endocrinol. Metab. 2007; 92: 45904597.
16. Ong S.C., Schoder H., Patel S.G. et al. Diagnostic accuracy
of 18FFDG PET in restaging patients with medullary thyroid
carcinoma and elevated calcitonin levels. J. Nucl. Med. 2007;
48: 501507.
17. Gourgiotis L., Sarlis N.J., Reynolds J.C. et al. Localization of
medullary thyroid carcinoma metastasis in a multiple endocrine neoplasitype 2A patient by 6[18F]fluo
rodopamine positron emission tomography. J. Clin.
Endocrinol. Metab. 2003; 88: 637641.
18. Koopmans K.P., de Groot J.W., Plukker J.T. et al. 18Fdihy
droxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 2008; 49: 524531.
19. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New
response evaluation criteria in solid tumours: revised RECIST
guideline (version 1.1). Eur. J. Cancer. 2009; 45: 228247.
20. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guide
lines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of
Cancer, National Cancer Institute of the United States,
National Cancer Institute of Canada. J. Natl. Cancer Inst.
2000; 92: 205216.
21. McWilliams R.R., Giannini C., Hay I.D. et al. Management of
brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer. 2003; 98:
356362.
22. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and
treatment of brain metastases in thyroid carcinoma. J. Clin.
Endocrinol. Metab. 1997; 82: 36373642.
23. Salvati M., Frati A., Rocchi G., Masciangelo R. et al. Single
brain metastasis from thyroid cancer: report of twelve cases
and review of the literature. J. Neurooncol. 2001; 51: 3340.
24. Kim I.Y., Kondziolka D., Niranjan A. et al. Gamma knife radio
surgery for metastatic brain tumors from thyroid cancer.
J. Neurooncol. 2009; 93: 355359.
25. MontAlverne F., Vallee J.N., Cormier E. et al. Percutaneous
vertebroplasty for metastatic involvement of the axis. Am. J.
Neuroradiol. 2005; 26: 16411645.
26. Goetz M.P., Callstrom M.R., Charboneau J.W. et al. Percutaneous imageguided radiofrequency ablation of painful
metastases involving bone: a multicenter study. J. Clin.
Oncol. 2004; 22: 300306.
27. Simon C.J., Dupuy D.E. Percutaneous minimally invasive
therapies in the treatment of bone tumors: thermal ablation.
Semin. Musculoskelet. Radiol. 2006; 10: 137144.
28. Masala S., Manenti G., Roselli M. et al. Percutaneous com
bined therapy for painful sternal metastases: a radiofrequecy thermal ablation (RFTA) and cementoplasty protocol.
Anticancer. Res. 2007; 27: 42594262.
29. Toyota N., Naito A., Kakizawa H. et al. Radiofrequency ablation therapy combined with cementoplasty for painful bone
metastases: initial experience. Cardiovasc. Intervent. Radiol.
2005; 28: 578583.
30. Chiras J., Adem C., Vallee J.N. et al. Selective intraarterial
chemoembolization of pelvic and spine bone metastases.
Eur. Radiol. 2004; 14: 17741780.
31. Guzman R., DubachSchwizer S., Heini P. et al. Preoperative
transarterial embolization of vertebral metastases. Eur. Spine.
J. 2005; 14: 263268.
32. Baba Y., Hayashi S., Ueno K., Nakajo M. Bone cement used
as an embolic agent for active bleeding in vertebroplasty of
metastatic lesions. Acta Radiol. 2007; 48: 10241027.
33. Bernier M.O., Leenhardt L., Hoang C. et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab.
2001; 86: 15681573.
34. Zettinig G., Fueger B.J., Passler C. et al. Longterm followup
of patients with bone metastases from differentiated thyroid
carcinoma surgery or conventional therapy? Clin. Endocrinol.
2002; 56: 377382.
35. Brierley J.D., Tsang R.W. External beam radiation therapy for
thyroid cancer. Endocrinol. Metab. Clin. North. Am. 2008; 37:
497509.
36. Vitale G., Fonderico F., Martignetti A. et al. Pamidronate
improves the quality of life and induces clinical remission of
bone metastases in patients with thyroid cancer. Br. J.
Cancer. 2001; 84: 15861590.
37. Tsutsui H., Kubota M., Yamada M. et al. Airway stenting for
the treatment of laryngotracheal stenosis secondary to thy
roid cancer. Respirology. 2008; 13: 632638.
38. Deandreis D., Leboulleux S., Dromain C. et al. Role of FDG
PET/CT and chest CT in the followup of lung lesions treated
with radiofrequency ablation. Radiology. 2011; 258: 270276.
39. Berber E., Flesher N., Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. Wld J.
Surg. 2002; 26: 985990.
40. Mazzaglia P.J., Berber E., Milas M., Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver
metastases: a 10year experience evaluating predictors of
survival. Surgery. 2007; 142: 1019.
41. Wertenbroek M.W., Links T.P., Prins T.R. et al. Radio
frequency ablation of hepatic metastases from thyroid carcinoma. Thyroid. 2008; 18: 11051110.
42. Lorenz K., Brauckhoff M., Behrmann C. et al. Selective arte
rial chemoembolization for hepatic metastases from
medullary thyroid carcinoma. Surgery. 2005; 138: 986993,
discussion 993.
43. Fromigue J., De Baere T., Baudin E. et al. Chemoembolization for liver metastases from medullary thyroid carcinoma.
J. Clin. Endocrinol. Metab. 2006; 91: 24962499.
44. Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatiin patients with advanced thyroid carcinoma. Cancer. 1985;
56: 21552160.
45. Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of
doxorubicin plus cisplatin in advanced thyroid cancer: a
Southeastern Cancer Study Group Trial. Cancer Treat. Rep.
1986; 70: 405407.
46. Orlandi F., Caraci P., Berruti A. et al. Chemotherapy with
dacarbazine and 5fluorouracil in advanced medullary thyroid
cancer. Ann. Oncol. 1994; 5: 763765.
47. Wu L.T., Averbuch S.D., Ball D.W. et al. Treatment of
advanced medullary thyroid carcinoma with a combination of
cyclophosphamide, vincristine, and dacarbazine. Cancer.
1994; 73: 432436.
48. Schlumberger M., Abdelmoumene N., Delisle M.J.,
Couette J.E. Treatment of advanced medullary thyroid cancer
with an alternating combination of 5 FUstreptozocin and 5 FUdacarbazine. The Groupe dEtude des Tumeurs a
Calcitonine (GETC). Br. J. Cancer. 1995; 71: 363365.
49. Bajetta E., Rimassa L., Carnaghi C. et al. 5Fluorouracil,
dacarbazine, and epirubicin in the treatment of patients with
neuroendocrine tumors. Cancer. 1998; 83: 372378.
50. Petursson S.R. Metastatic medullary thyroid carcinoma.
Complete response to combination chemotherapy with
dacarbazine and 5fluorouracil. Cancer. 1988; 62: 18991903.
51. Nocera M., Baudin E., Pellegriti G. et al. Treatment of advanced medullary thyroid cancer with an alternating combination
of doxorubicinstreptozocin and 5 FUdacarbazine. GroupEtude des Tumeurs Calcitonine (GETC). Br. J. Cancer.
2000; 83: 715718.
52. Papewalis C., Wuttke M., Seissler J. et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor
rejection in neuroendocrine cancer. Clin. Cancer Res. 2008;
14: 42984305.
53. Iten F., Müller B., Schindler C. et al. Response to [90 Yttrium
DOTA]TOC treatment is associated with longterm survival
benefit in metastasized medullary thyroid cancer: a phase II
clinical trial. Clin. Cancer Res. 2007; 13: 66966702.
54. KraeberBodere F., Goldenberg D.M., Chatal J.F., Barbet J.
Pretargeted radioimmunotherapy in the treatment of meta
static medullary thyroid cancer. Curr. Oncol. 2009; 16: 38.
55. Pasieka J.L., McEwan A.J., Rorstad O. The palliative role of
131 IMIBG and 111 Inoctreotide therapy in patients with
metastatic progressive neuroendocrine neoplasms. Surgery.
2004; 136: 12181226.
56. Wells S.A. Jr., Santoro M. Targeting the RET pathway in thy
roid cancer. Clin. Cancer Res. 2009; 15: 71197123.
57. Capp C., Wajner S.M., Siqueira D.R. et al. Increased expression of vascular endothelial growth factor and its receptors,
VEGFR1 and VEGFR2, in medullary thyroid carcinoma.
Thyroid. 2010; 20: 863871.
58. Cohen E.E.W., Rosen L.S., Vokes E.E. et al. Axitinib is an
active treatment for all histologic subtypes of advanced thy
roid cancer: Results from a phase II study. J. Clin. Oncol.
2008; 26: 47084713.
59. Nemunaitis J.J. et al. Phase I doseescalation study of E7080,
a multikinase inhibitor, in patients with advanced solid tumors.
J. Clin. Oncol. (Meeting Abstracts). 2008; 26: 14583.
60. Schlumberger M., Elisei R., Bastholt L. et al. Phase II study of
safety and efficacy of motesanib (AMG 706) in patients with
progressive or symptomatic, advanced or metastatic
medullary thyroid cancer. J. Clin. Oncol. 2009; 27: 37943801.
61. Bible K.C. et al. Phase 2 trial of pazopanib in rapidly progressive, metastatic, medullary thyroid cancer. Thyroid (Meeting
Abstracts). 2009; 19: S110.
62. Lam E.T., Ringel M.D., Kloos R.T. et al. Phase II clinical trial of
sorafenib in metastatic medullary thyroid cancer. J. Clin.
Oncol. 2010; 28: 23232330.
63. De Souza J.A. et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J. Clin. Oncol. (Meeting Abstracts). 2010;
28: 5504.
64. Carr L.L., Mankoff D.A., Goulart B.H. et al. Phase II study of
daily sunitinib in FDGPETpositive, iodinerefractory differentiated thyroid cancer and metastatic medullary carcinoma
of the thyroid with functional imaging correlation. Clin.
Cancer Res. 2010; 16: 52605268.
65. Kurzrock R., Sherman S.I., Ball D.W. et al. Activity of XL184
(cabozantinib), an oral tyrosine kinase inhibitor, in patients
with medullary thyroid cancer. J. Clin. Oncol. 2011; 29:
26602666.
66. Papotti M., Olivero M., Volante M. et al. Expression of
hepatocyte growth factor (HGF) and its receptor (MET) in
medullary carcinoma of the thyroid. Endocr. Pathol. 2000;
11: 1930.
67. Wells S., Gosnell J., Gagel R. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary
medullary thyroid cancer. J. Clin. Oncol. 2010; 28: 767772.
68. Robinson B.G., PazAres L., Krebs A. et al. Vandetanib
(100 mg) in patients with locally advanced or metastatic
hereditary medullary thyroid cancer. J. Clin. Endocrinol.
Metab. 2010; 95: 26642671.
69. Wells S.A., Robinson B.G., Gagel R.F. et al. Vandetanib in
patients with locally advanced or metastatic medullary thyroid
cancer: a randomized, doubleblind phase III trial (ZETA).
J. Clin. Oncol. 2012; 30: 134141.
70. Hong D.S., Cabanillas M.E., Wheler J. et al. Inhibition of the
Ras/Raf/MEK/ERK and RET kinase pathways with the
combination of the multikinase inhibitor sorafenib and the far
nesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 2011;
96: 9971005.
71. Hoff P.M. et al. Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic
medullary thyroid carcinomas (MTC). J. Clin. Oncol. (Meeting
Abstracts). 2006; 24: 13048.
72. Jensen R.T. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin. Gastrointest. Dis.
1999; 10: 156172.
73. Rambaud J.C., Jian R., Flourie B. et al. Pathophysiological
study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role
of shortened colonic transit time. Gut. 1988; 29: 537543.
74. Barbosa S.L., Rodien P., Leboulleux S. et al. Ectopic adrenocorticotropic hormone syndrome in medullary carcinoma of
the thyroid: a retrospective analysis and review of the literature. Thyroid. 2005; 15: 618623.
75. Mahler C., Verhelst J., de Longueville M., Harris A. Longterm
treatment of metastatic medullary thyroid carcinoma with the
somatostatin analogue octreotide. Clin. Endocrinol. 1990;
33: 261269.
76. Lupoli G., Cascone E., Arlotta F. et al. Treatment of advanced
medullary thyroid carcinoma with a combination of recombinant interferon alpha2b and octreotide. Cancer. 1996; 78:
11141118.
77. Kamenicky P., Droumaguet C., Salenave S. et al. Mitotane,
metyrapone, and ketoconazole combination therapy as an
alternative to rescue adrenalectomy for severe ACTHdepen
dent Cushings syndrome. J. Clin. Endocrinol. Metab. 2011;
96: 27962804.

2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer

M. Schlumbergera, L. Bastholtb, H. Drallec, B. Jarzabd, F. Pacinie, J.W.A. Smitf The European Thyroid Association Task Force

Distant metastases are the main cause of death in patients with medullary thyroid cancer (MTC). These 21 recommendations focus on MTC patients with distant metastases and a detailed followup protocol of patients with biochemical or imaging evidence of disease, selection criteria for treatment, and treatment modalities, including local and systemic treatments based on the results of recent trials. Asymptomatic patients with low tumor burden and stable disease may benefit from local treatment modalities and can be followed up at regular intervals of time. Imaging is usually performed every 612 months, or at longer intervals of time depending on the doubling times of serum calcitonin and carcinoembryonic antigen levels. Patients with symptoms, large tumor burden and progression on imaging should receive systemic treatment. Indeed, major progress has recently been achieved with novel targeted therapies using kinase inhibitors directed against RET and VEGFR, but further research is needed to improve the outcome of these patients

Keywords:
medullary thyroid cancer, metastases, tyrosine kinase inhibitors, RET.

Новости   Магазин   Журналы   Контакты   Правила   Доставка   О компании  
ООО Издательский дом ВИДАР-М, 2016